PLUS THERAPEUTICS, INC.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
CNSY$0.68+19.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(6,946) | $(17,401) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 96 | 146 |
| Stock-based compensation expense | 1,022 | 148 |
| Noncash financing expenses | — | 3,211 |
| Noncash interest expense | 17 | — |
| Change in fair value of derivative instruments | — | 9,143 |
| Accretion of discount on short-term investments | (21) | — |
| Operating lease right-of-use asset amortization | 13 | 35 |
| Gain on sale of assets | — | (16) |
| Increases (decreases) in cash caused by changes in operating assets and liabilities: | ||
| Grant receivable | (1,028) | 571 |
| Other assets | 146 | 74 |
| Accounts payable and accrued expenses | 489 | (2,418) |
| Change in operating lease liabilities | (13) | (35) |
| Other liabilities | (13) | — |
| Deferred grant liability | — | 370 |
| Net cash used in operating activities | (6,238) | (6,172) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (818) | (3) |
| Proceeds from sale of property and equipment | — | 30 |
| Purchase of short-term investments | (9,701) | — |
| Redemption of short-term investments | 1,986 | 3,531 |
| Net cash (used in) provided by investing activities | (8,533) | 3,558 |
| Cash flows from financing activities: | ||
| Proceeds from credit facility | 1,000 | — |
| Repayment of credit facility | (1,100) | (3,292) |
| Proceeds from issuance of notes payable and warrants | — | 3,738 |
| Repayment of notes payable | — | (3,703) |
| Proceeds from sale of common stock, pre-funded warrants and warrants | — | 14,780 |
| Proceeds from exercise of warrants | — | 882 |
| Proceeds from underwritten public offering | 15,000 | — |
| Payment to investors pursuant to Letter Agreement | (4,502) | — |
| Offering costs for sale of common stock | (1,363) | — |
| Net cash provided by financing activities | 9,035 | 12,405 |
| Net change in cash and cash equivalents | (5,736) | 9,791 |
| Cash, restricted cash and cash equivalents at beginning of period | 8,758 | 76 |
| Cash, restricted cash and cash equivalents at end of period | $3,022 | $9,867 |
| Supplemental disclosure of cash flows information: | ||
| Cash paid during period for: | ||
| Interest | $— | $539 |
| Supplemental schedule of non-cash investing and financing activities: | ||
| Exchange of warrants for notes payable | $— | $3,694 |
| Redemption of notes by issuance of common stock, pre-funded warrants and warrants | $— | $3,512 |
| Unpaid offering cost | $— | $202 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.